Des études mono-bras aux études de comparaison externe. Considérations méthodologiques et recommandations

[1]  M. Golden,et al.  Single-Arm Open-Label Clinical Trial of Two Grams of Aztreonam for the Treatment of Neisseria gonorrhoeae , 2020, Antimicrobial Agents and Chemotherapy.

[2]  J. Foster,et al.  Single-Arm Phase II Trials of Combination Therapies: A Review of the CTEP Experience 2008-2017. , 2019, Journal of the National Cancer Institute.

[3]  Huseyin Naci,et al.  A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness. , 2019, Journal of clinical epidemiology.

[4]  X. Paoletti,et al.  Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines? , 2018, British Journal of Cancer.

[5]  Sofia Dias,et al.  Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[6]  Nicky J Welton,et al.  NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE , 2016 .

[7]  Michael A Proschan,et al.  A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. , 2016, The New England journal of medicine.

[8]  M. Baron,et al.  Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial , 2016, The Lancet.

[9]  S. Lepreux,et al.  Imatinib mesylate in scleroderma‐associated diffuse skin fibrosis: a phase II multicentre randomized double‐blinded controlled trial , 2012, The British journal of dermatology.

[10]  Mei Lu,et al.  Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[11]  K. Jack Ishak,et al.  No Head-to-Head Trial? Simulate the Missing Arms , 2012, PharmacoEconomics.

[12]  Eric Q. Wu,et al.  Comparative Effectiveness Without Head-to-Head Trials , 2012, PharmacoEconomics.

[13]  C. Tournigand,et al.  Progression-free survival ratio as end point for phase II trials in advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Gordon,et al.  Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial , 2011, Annals of the rheumatic diseases.

[15]  Sander Greenland,et al.  Bias Analysis , 2011, International Encyclopedia of Statistical Science.

[16]  Michael Bittner,et al.  Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Donna Niedzwiecki,et al.  Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.